Therapeutics & Diagnostics

• The molecular mechanism of treatment resistance in glioblastoma now revealed as overexpression of PP2A inhibitor PME-1 (Kaur et al., Cancer Res, Epub 2016)
• Efficient therapy is accomplished by combining the blocking of PME-1 and/or HDAC4 with chemotherapy
• Significant evidence in a xenograft mouse model
• WO2014009609A1, EP2872631B1; WO2014033367A1, EP2890986B1; WO2012175798A2, EP2723450B1, JP6001655B2, US9476050B2

• Genetic predisposition to aggressive PrCa in Caucasians now traced to two synergistic germline mutations (ms submitted)    
• Dual carriers of the two gene variants have a high risk of developing clinically relevant prostate cancer (OR 23.4) and especially aggressive PrCa such as CRPC (OR 36.6).
• Provides a new tool for patient stratification and for improved personalized care with more informed therapeutic actions
• WO2017203100A1

• Used in monotherapy or as adjuvants to stimulate immune response towards malignant cells
• Significantly suppressed thegrowth of melanoma in a xenograft mouse model
• WO2012175813A1; WO2017109288A1; WO2017207542A1

• Two new biomarkers:
  • A novel oncogene variant predicting poor survival in AML (HR 1.51)
  • A cell signaling protein predicting relapse after chemotherapy (HR 3.7)
• Facilitate stratification of patients with poorest prognosis for the most efficient therapies
• Independent of current risk grouping – provide significant added value for personalized therapy
• Priority patent application FI20176032 (public 05/2019)

Efficient elimination of the tumor cell-derived immunosuppressant adenosine

• Invention directly combinable with therapeutic antibodies (e.g. anti-CD73 / anti-CD39) 
• Targets aggressive cancers such as melanoma
• Efficacy studies in mouse cancer models (ongoing)
• Priority patent application public 07/2019